Browsing Tag
MD Anderson Cancer Center
5 posts
Will intravenous oncolytic viruses finally overcome metastatic delivery barriers?
ViroMissile, Inc. expands IDOV-Immune into U.S. cancer centers after FDA IND clearance. Explore what this means for systemic viral oncology.
February 20, 2026
Chimeric Therapeutics reports early success in frontline cell therapy for AML in ADVENT-AML Phase 1B trial
Chimeric Therapeutics reports promising early results in its ADVENT-AML trial, with 2 of 3 patients showing remission. Find out how CHM is advancing cell therapy.
May 15, 2025
Pfizer’s BRAFTOVI regimen doubles response rates for metastatic colorectal cancer
Pfizer Inc. has unveiled compelling findings from the Phase 3 BREAKWATER trial, highlighting the efficacy of its BRAFTOVI…
January 26, 2025
TriSalus Life Sciences’ SD-101 yields positive outcomes from Phase 1 trial in uveal melanoma with liver metastases
TriSalus Life Sciences made a significant contribution to the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting…
November 5, 2023
280Bio initiates Phase 1 clinical study for YL-17231 after FDA approval
In a significant breakthrough for 280Bio, Inc., a clinical-stage biotechnology company, the US Food and Drug Administration (FDA)…
July 10, 2023